新华制药：前三季度净利润同比下降25.53%

Core Viewpoint - Xinhua Pharmaceutical (000756) reported a decline in net profit for Q3 2025 despite a revenue increase, indicating challenges in maintaining profitability amid competitive market pressures [1] Financial Performance - In Q3 2025, the company achieved revenue of 2.124 billion yuan, representing a year-on-year growth of 6.1% [1] - The net profit attributable to shareholders was 32.4642 million yuan, showing a significant year-on-year decline of 58.74% [1] - For the first three quarters of 2025, total revenue reached 6.763 billion yuan, with a modest year-on-year growth of 0.42% [1] - The net profit for the first three quarters was 256 million yuan, down 25.53% compared to the previous year [1] Market Strategy - The decline in net profit is primarily attributed to the company's strategic decision to adjust product prices in response to intense market competition, aiming to consolidate or increase market share [1]